CSTL News

Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma’s i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB

DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk

Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB

Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas

Form 8-K

Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results

Prospective Validation Study in JAAD Demonstrates Castle Biosciences’ AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis

Merlin CP-GEP Becomes the First and Only Gene Expression Profile (GEP) Test Recommended by NCCN® Cutaneous Melanoma Guidelines to Assess Metastatic Risk

Orion Nuclear Energy Corporation and Constellis Announce Strategic Collaboration to Advance Security Standards for Nuclear and Critical Infrastructure

Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026